Safety and efficacy analysis of DEB-TACE treatment in elderly patients with hepatocellular carcinoma: a comparative cohort study

Qing Yang(Guangzhou University of Chinese Medicine), Changsheng Shi(Wenzhou Medical University), Fangpeng Ye(Wenzhou Medical University), Ya Luo(Wenzhou Medical University), Bingru Zheng(Wenzhou Medical University), Xiaosheng Jin(Tongde Hospital of Zhejiang Province), Xiangpang Xie(Wenzhou Medical University), Zhenjing Shi(Wenzhou Medical University)
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
January 1, 2018
10.3727/096504018x15223171140640
Cited by 5

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus
|Immunity|2016|378
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
|British Journal of Cancer|2018|156
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
|Science Translational Medicine|2019|138